These drugs either source all main ingredients from China or are finished in the country. Credit: Gundula Vogel from Pixabay.

Visit our Covid-19 microsite for the latest coronavirus news, analysis and updates

Follow the latest updates of the outbreak on our timeline.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

The US Food and Drug Administration (FDA) has identified approximately 20 drugs at risk of shortage due to the ongoing coronavirus outbreak.

These drugs either source all main ingredients from China or are finished in the country, noted Reuters.

When the agency contacted manufacturers of the identified drugs, none reported an expected shortage due to the epidemic.

FDA spokeswoman Stephanie Caccomo was quoted as saying: “We have been in contact with those firms to understand if they face any drug shortage risks due to the outbreak. None of these firms has reported any shortage to date.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

“We will continue to remain in contact with the manufacturers so that we can best help mitigate any potential issues in the future.”

Since 24 January, the agency also notified more than 180 companies to alert the FDA in case of any expected shortages. Also, the FDA asked the manufacturers to assess their entire supply chain, said CNBC.

In a separate development, US President Donald Trump’s administration is seeking $2.5bn from Congress to combat the coronavirus.

According to the White House, more than $1bn of the funds would go towards developing a vaccine, with the remaining allocated for therapeutics and stockpiling of protective equipment such as masks.